Drug Profile
Research programme: hepatitis C therapies - Ligand/Roche
Alternative Names: HCV prodrugs - Ligand/Roche; HCV therapies - Ligand/Roche; MB 11362Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Metabasis Therapeutics; Roche
- Developer Ligand Pharmaceuticals; Roche
- Class Nucleosides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA
- 29 Jan 2010 Metabasis Therapeutics has been acquired by Ligand Pharmaceuticals
- 09 Jun 2009 Preclinical development is ongoing